Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 257 articles:
HTML format
Text format



Single Articles


    April 2019
  1. WITZIG TE, Inwards D
    Acalabrutinib for Mantle Cell Lymphoma.
    Blood. 2019 Apr 9. pii: blood.2019852368. doi: 10.1182/blood.2019852368.
    PubMed     Text format     Abstract available


  2. ARMAND P, Chen YB, Redd RA, Joyce RM, et al
    PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.
    Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215.
    PubMed     Text format     Abstract available


    March 2019
  3. SONG JY, Herrera AF
    CAR T cells mimicking an aggressive lymphoma.
    Blood. 2019;133:1517.
    PubMed     Text format    


  4. GODFREY J, Tumuluru S, Bao R, Leukam M, et al
    PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype.
    Blood. 2019 Mar 25. pii: blood-2018-10-879015. doi: 10.1182/blood-2018-10-879015
    PubMed     Text format     Abstract available



  5. Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132(16):1635-1646.
    Blood. 2019;133:1384-1385.
    PubMed     Text format    


  6. ZELENETZ AD, Salles G, Mason KD, Casulo C, et al
    Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
    Blood. 2019 Mar 8. pii: blood-2018-11-880526. doi: 10.1182/blood-2018-11-880526.
    PubMed     Text format     Abstract available


  7. ALLAN JM
    Genetic susceptibility to breast cancer in lymphoma survivors.
    Blood. 2019;133:1004-1006.
    PubMed     Text format    


    February 2019
  8. CAIRO MS
    A new Burkitt "look-alike" lymphoma.
    Blood. 2019;133:889-891.
    PubMed     Text format    


  9. PEMMARAJU N, Kantarjian H, Nastoupil L, Dupuis M, et al
    Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
    Blood. 2019 Feb 22. pii: blood-2019-01-897637. doi: 10.1182/blood-2019-01-897637
    PubMed     Text format    


  10. GARCES S, Sriganeshan V
    Fibrin-associated diffuse large B-cell lymphoma confined to a cardiac myxoma.
    Blood. 2019;133:882.
    PubMed     Text format    


  11. HIRAYAMA AV, Gauthier J, Hay KA, Voutsinas JM, et al
    The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells.
    Blood. 2019 Feb 19. pii: blood-2018-11-887067. doi: 10.1182/blood-2018-11-887067
    PubMed     Text format     Abstract available


  12. LURAIN K, Polizzotto MN, Aleman K, Bhutani M, et al
    Viral, immunologic, and clinical features of primary effusion lymphoma.
    Blood. 2019 Feb 19. pii: blood-2019-01-893339. doi: 10.1182/blood-2019-01-893339
    PubMed     Text format     Abstract available


  13. HEAVICAN TB, Bouska A, Yu J, Lone W, et al
    Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
    Blood. 2019 Feb 19. pii: blood-2018-09-872549. doi: 10.1182/blood-2018-09-872549
    PubMed     Text format     Abstract available


  14. BORCHMANN S, Joffe E, Moskowitz CH, Zelenetz AD, et al
    Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
    Blood. 2019 Feb 15. pii: blood-2018-10-877761. doi: 10.1182/blood-2018-10-877761
    PubMed     Text format     Abstract available


  15. SU RJ, Said J
    Intraocular toxoplasmosis mimicking vitreous lymphoma.
    Blood. 2019;133:767.
    PubMed     Text format    



  16. Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670-2681.
    Blood. 2019;133:620.
    PubMed     Text format    


  17. HSI ED, Li H, Nixon AB, Schoder H, et al
    Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
    Blood. 2019 Feb 5. pii: blood-2018-08-870915. doi: 10.1182/blood-2018-08-870915.
    PubMed     Text format     Abstract available


    January 2019
  18. LYAPICHEV KA, You MJ
    Unusual presentation of classic Hodgkin lymphoma.
    Blood. 2019;133:502.
    PubMed     Text format    


  19. CASULO C, Barr PM
    How I treat early relapsing follicular lymphoma.
    Blood. 2019 Jan 30. pii: blood-2018-08-822148. doi: 10.1182/blood-2018-08-822148
    PubMed     Text format     Abstract available


  20. VON HOFF L, Kargel E, Franke V, McShane E, et al
    Autocrine LTA signaling drives NF-kappaB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
    Blood. 2019 Jan 29. pii: blood-2018-08-871293. doi: 10.1182/blood-2018-08-871293
    PubMed     Text format     Abstract available


  21. MARTIN P, Bartlett NL, Blum KA, Park S, et al
    A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood. 2019 Jan 28. pii: blood-2018-11-886457. doi: 10.1182/blood-2018-11-886457
    PubMed     Text format     Abstract available


  22. MOSHREF RAZAVI H, Hrynchak M
    Unusual presentation of Burkitt-like lymphoma with 11q aberration in an elderly patient.
    Blood. 2019;133:381.
    PubMed     Text format    


  23. MATSUE K, Abe Y, Kitadate A, Miura D, et al
    Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma.
    Blood. 2019 Jan 15. pii: blood-2018-11-887570. doi: 10.1182/blood-2018-11-887570
    PubMed     Text format    


  24. GRANDE BM, Gerhard DS, Jiang A, Griner NB, et al
    Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma.
    Blood. 2019 Jan 7. pii: blood-2018-09-871418. doi: 10.1182/blood-2018-09-871418.
    PubMed     Text format     Abstract available


    December 2018
  25. ANDOR N, Simonds EF, Czerwinski DK, Chen J, et al
    Single-cell RNA-Seq of lymphoma cancers reveals malignant B cell types and co-expression of T cell immune checkpoints.
    Blood. 2018 Dec 27. pii: blood-2018-08-862292. doi: 10.1182/blood-2018-08-862292
    PubMed     Text format     Abstract available


  26. OPSTAL-VAN WINDEN AWJ, de Haan HG, Hauptmann M, Schmidt MK, et al
    Genetic susceptibility to radiation-induced breast cancer after Hodgkin Lymphoma.
    Blood. 2018 Dec 20. pii: blood-2018-07-862607. doi: 10.1182/blood-2018-07-862607
    PubMed     Text format     Abstract available


  27. GROMMES C, Tang SS, Wolfe J, Kaley TJ, et al
    Phase Ib trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Blood. 2018 Dec 19. pii: blood-2018-09-875732. doi: 10.1182/blood-2018-09-875732
    PubMed     Text format     Abstract available


  28. WAGENER R, Seufert J, Raimondi F, Bens S, et al
    The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
    Blood. 2018 Dec 19. pii: blood-2018-07-864025. doi: 10.1182/blood-2018-07-864025
    PubMed     Text format     Abstract available


  29. JANZ S
    New wrinkle on deubiquitination in B-cell lymphoma.
    Blood. 2018;132:2529-2530.
    PubMed     Text format    


  30. MARTIN-GARCIA D, Navarro A, Valdes-Mas R, Clot G, et al
    CCND2 and CCND3 hijack immunoglobulin light chain enhancers in cyclin D1-negative mantle cell lymphoma.
    Blood. 2018 Dec 11. pii: blood-2018-07-862151. doi: 10.1182/blood-2018-07-862151
    PubMed     Text format     Abstract available


  31. MOHANTY A, Sandoval N, Phan A, Nguyen TV, et al
    Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
    Blood. 2018 Dec 10. pii: blood-2018-05-851667. doi: 10.1182/blood-2018-05-851667
    PubMed     Text format     Abstract available


  32. MENDEVILLE M, Roemer MGM, van den Hout MFCM, Los-de Vries GT, et al
    Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.
    Blood. 2018 Dec 3. pii: blood-2017-12-822171. doi: 10.1182/blood-2017-12-822171.
    PubMed     Text format    


    November 2018
  33. HUTCHINGS M
    A small change makes a big difference in Hodgkin lymphoma.
    Blood. 2018;132:2214-2215.
    PubMed     Text format    


  34. QU X, Li H, Braziel RM, Passerini V, et al
    Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016.
    Blood. 2018 Nov 16. pii: blood-2018-07-865428. doi: 10.1182/blood-2018-07-865428
    PubMed     Text format     Abstract available


  35. BRADY JL, Binkley MS, Hajj C, Chelius M, et al
    Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG.
    Blood. 2018 Nov 16. pii: blood-2018-04-843540. doi: 10.1182/blood-2018-04-843540
    PubMed     Text format     Abstract available


  36. DREYLING M, Klapper W, Rule S
    Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
    Blood. 2018 Nov 1. pii: blood-2017-08-737502. doi: 10.1182/blood-2017-08-737502.
    PubMed     Text format     Abstract available


    October 2018
  37. GRALEWSKI J, Post GR
    Cutaneous intralymphatic CD30(+) pseudolymphoma: a reactive condition mimicking lymphoma.
    Blood. 2018;132:1859.
    PubMed     Text format    


  38. KANAAN C, Burroni B
    Unusual location of a follicular lymphoma with features of pediatric-type follicular lymphoma.
    Blood. 2018;132:1725.
    PubMed     Text format    


  39. DANIEL R, Chan RY
    Hyperviscosity syndrome in splenic marginal zone lymphoma.
    Blood. 2018;132:1627.
    PubMed     Text format    


  40. NASTOUPIL LJ
    Next-generation therapy for follicular lymphoma.
    Blood. 2018;132:1465-1467.
    PubMed     Text format    


  41. LEMONNIER F, Dupuis J, Sujobert P, Tournillhac O, et al
    Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.
    Blood. 2018 Oct 2. pii: blood-2018-04-840538. doi: 10.1182/blood-2018-04-840538.
    PubMed     Text format    


    September 2018
  42. MOSKOWITZ CH, Walewski J, Nademanee A, Masszi T, et al
    Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
    Blood. 2018 Sep 28. pii: blood-2018-07-861641. doi: 10.1182/blood-2018-07-861641
    PubMed     Text format     Abstract available


  43. TUN HW, Johnston PB, DeAngelis LM, Atherton PJ, et al
    Phase I study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreo-retinal lymphoma.
    Blood. 2018 Sep 27. pii: blood-2018-02-835496. doi: 10.1182/blood-2018-02-835496
    PubMed     Text format     Abstract available


  44. MOTTOK A, Wright G, Rosenwald A, Ott G, et al
    Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.
    Blood. 2018 Sep 26. pii: blood-2018-05-851154. doi: 10.1182/blood-2018-05-851154
    PubMed     Text format     Abstract available


  45. ELSHIEKH M, Naresh KN
    A rare case of renal intravascular NK/T-cell lymphoma.
    Blood. 2018;132:1354.
    PubMed     Text format    


  46. MUSILOVA K, Devan J, Cerna K, Seda V, et al
    miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
    Blood. 2018 Sep 13. pii: blood-2018-06-855502. doi: 10.1182/blood-2018-06-855502
    PubMed     Text format     Abstract available


  47. LI L, Zhang J, Chen J, Xu-Monette ZY, et al
    B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
    Blood. 2018 Sep 12. pii: blood-2018-03-841015. doi: 10.1182/blood-2018-03-841015
    PubMed     Text format     Abstract available


  48. MEHTA-SHAH N, Clemens MW, Horwitz SM
    How I treat breast implant-associated anaplastic large cell lymphoma.
    Blood. 2018 Sep 12. pii: blood-2018-03-785972. doi: 10.1182/blood-2018-03-785972
    PubMed     Text format     Abstract available


  49. KAMIJO H, Miyagaki T, Shishido-Takahashi N, Nakajima R, et al
    Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Blood. 2018 Sep 7. pii: blood-2018-04-845834. doi: 10.1182/blood-2018-04-845834.
    PubMed     Text format     Abstract available


  50. SUD A, Thomsen H, Orlando G, Forsti A, et al
    Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.
    Blood. 2018 Sep 7. pii: blood-2018-06-855296. doi: 10.1182/blood-2018-06-855296.
    PubMed     Text format     Abstract available


  51. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.
    PubMed     Text format    


  52. DIEFENBACH CS
    CART19 in Hodgkin lymphoma: are we driving the right model?
    Blood. 2018;132:982-983.
    PubMed     Text format    


  53. RUAN J, Martin P, Christos P, Cerchietti L, et al
    Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
    Blood. 2018 Sep 4. pii: blood-2018-07-859769. doi: 10.1182/blood-2018-07-859769.
    PubMed     Text format     Abstract available


    August 2018
  54. KOBE C, Goergen H, Baues C, Kuhnert G, et al
    Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
    Blood. 2018 Aug 30. pii: blood-2018-05-852129. doi: 10.1182/blood-2018-05-852129
    PubMed     Text format     Abstract available


  55. MADDOCKS K
    Update on Mantle Cell Lymphoma.
    Blood. 2018 Aug 28. pii: blood-2018-03-791392. doi: 10.1182/blood-2018-03-791392
    PubMed     Text format     Abstract available


  56. SHIMADA K, Hayakawa F, Kiyoi H
    Biology and management of primary effusion lymphoma.
    Blood. 2018 Aug 28. pii: blood-2018-03-791426. doi: 10.1182/blood-2018-03-791426
    PubMed     Text format     Abstract available


  57. TIMMERMAN J
    The run-down immunologic neighborhood in Hodgkin lymphoma.
    Blood. 2018;132:770-771.
    PubMed     Text format    


  58. HELLMUTH JC, Louissaint A Jr, Szczepanowski M, Haebe S, et al
    Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles.
    Blood. 2018 Aug 20. pii: blood-2018-03-837252. doi: 10.1182/blood-2018-03-837252
    PubMed     Text format     Abstract available


  59. PONZONI M, Campo E, Nakamura S
    INTRAVASCULAR LARGE B-CELL LYMPHOMA: A CHAMELEON WITH MULTIPLE FACES AND MANY MASKS.
    Blood. 2018 Aug 15. pii: blood-2017-04-737445. doi: 10.1182/blood-2017-04-737445
    PubMed     Text format     Abstract available


  60. DABAJA BS, Hoppe BS, Plastaras JP, Newhauser W, et al
    PROTON THERAPY FOR ADULTS WITH MEDIASTINAL LYMPHOMAS: THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) GUIDELINES.
    Blood. 2018 Aug 14. pii: blood-2018-03-837633. doi: 10.1182/blood-2018-03-837633
    PubMed     Text format     Abstract available


  61. LU X, Fernando T, Lossos C, Yusufova N, et al
    PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
    Blood. 2018 Aug 6. pii: blood-2018-02-831438. doi: 10.1182/blood-2018-02-831438.
    PubMed     Text format     Abstract available


  62. MORSCHHAUSER F, Salles G, Le Gouill S, Tilly H, et al
    An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
    PubMed     Text format     Abstract available


    July 2018
  63. EICHENAUER DA, Plutschow A, Schroder L, Fuchs M, et al
    Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Blood. 2018 Jul 31. pii: blood-2018-02-836437. doi: 10.1182/blood-2018-02-836437
    PubMed     Text format     Abstract available


  64. MARKS LJ, McCarten K, Pei Q, Friedman DL, et al
    Pericardial Effusion in Hodgkin Lymphoma: A Report from the Children's Oncology Group AHOD0031.
    Blood. 2018 Jul 30. pii: blood-2018-02-834465. doi: 10.1182/blood-2018-02-834465
    PubMed     Text format    


  65. SONG TL, Nairismagi ML, Laurensia Y, Lim JQ, et al
    Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma.
    Blood. 2018 Jul 27. pii: blood-2018-01-829424. doi: 10.1182/blood-2018-01-829424
    PubMed     Text format     Abstract available


  66. STRAUS DJ, Jung SH, Pitcher B, Kostakoglu L, et al
    CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Blood. 2018 Jul 26. pii: blood-2018-01-827246. doi: 10.1182/blood-2018-01-827246
    PubMed     Text format     Abstract available



  67. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.
    Blood. 2018;132:458-459.
    PubMed     Text format    


  68. GOLDSTEIN JS, Nastoupil LJ, Han X, Jemal A, et al
    Disparities in survival by insurance status in follicular lymphoma.
    Blood. 2018 Jul 24. pii: blood-2018-03-839035. doi: 10.1182/blood-2018-03-839035
    PubMed     Text format     Abstract available


  69. HOSER D, Schon C, Loddenkemper C, Lohneis P, et al
    Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice.
    Blood. 2018 Jul 12. pii: blood-2018-02-834036. doi: 10.1182/blood-2018-02-834036
    PubMed     Text format     Abstract available


  70. ILLERHAUS G, Schorb E, Kasenda B
    Novel agents for primary central nervous system lymphoma (PCNSL): evidence and perspectives.
    Blood. 2018 Jul 9. pii: blood-2018-01-791558. doi: 10.1182/blood-2018-01-791558.
    PubMed     Text format     Abstract available


  71. GORDON LI
    Getting to transplant in Hodgkin lymphoma: BVB.
    Blood. 2018;132:1-3.
    PubMed     Text format    


  72. GIULINO-ROTH L
    How I treat primary mediastinal B-cell lymphoma.
    Blood. 2018 Jul 5. pii: blood-2018-04-791566. doi: 10.1182/blood-2018-04-791566.
    PubMed     Text format     Abstract available


    June 2018
  73. ALRABEH R, Hao S
    "Double-expressor" intravascular large B-cell lymphoma involving the female genital tract.
    Blood. 2018;131:2993.
    PubMed     Text format    


  74. PATIL A, Manzano M, Gottwein E
    CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Blood. 2018 Jun 28. pii: blood-2018-01-828418. doi: 10.1182/blood-2018-01-828418
    PubMed     Text format     Abstract available


  75. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991
    PubMed     Text format    


  76. SVOBODA J, Rheingold SR, Gill SI, Grupp SA, et al
    Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma.
    Blood. 2018 Jun 20. pii: blood-2018-03-837609. doi: 10.1182/blood-2018-03-837609
    PubMed     Text format     Abstract available


  77. OISHI N, Brody GS, Ketterling RP, Viswanatha DS, et al
    Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.
    Blood. 2018 Jun 19. pii: blood-2017-12-821868. doi: 10.1182/blood-2017-12-821868
    PubMed     Text format    


  78. KALPADAKIS C, Pangalis GA, Sachanas S, Tsirkinidis P, et al
    Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
    Blood. 2018 Jun 18. pii: blood-2018-02-833608. doi: 10.1182/blood-2018-02-833608
    PubMed     Text format    


  79. CHOW VA, Shadman M, Gopal AK
    Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma.
    Blood. 2018 Jun 18. pii: blood-2018-04-839217. doi: 10.1182/blood-2018-04-839217
    PubMed     Text format     Abstract available


  80. FLERLAGE JE, Metzger ML, Bhakta N
    The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?
    Blood. 2018 Jun 12. pii: blood-2018-01-778548. doi: 10.1182/blood-2018-01-778548
    PubMed     Text format     Abstract available


  81. CADER FZ, Schackmann RCJ, Hu X, Wienand K, et al
    Mass cytometry of Hodgkin lymphoma reveals a CD4(+) exhausted T-effector and T-regulatory cell rich microenvironment.
    Blood. 2018 Jun 7. pii: blood-2018-04-843714. doi: 10.1182/blood-2018-04-843714.
    PubMed     Text format     Abstract available


  82. BOUDESCO C, Verhoeyen E, Martin L, Chassagne-Clement C, et al
    HSP110 sustains chronic NF-kappaB signaling in activated B cell diffuse large B cell lymphoma through MyD88 stabilization.
    Blood. 2018 Jun 5. pii: blood-2017-12-819706. doi: 10.1182/blood-2017-12-819706.
    PubMed     Text format     Abstract available


  83. ADAMS HJA, Kwee TC
    Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven.
    Blood. 2018 Jun 1. pii: blood-2018-04-845438. doi: 10.1182/blood-2018-04-845438.
    PubMed     Text format    


    May 2018
  84. NAKAYAMA S, Matsuda M
    25-Hydroxyvitamin D3-1alpha-hydroxylase- and multiple cytokine-producing diffuse large B-cell lymphoma.
    Blood. 2018;131:2271.
    PubMed     Text format    


  85. GOPAL S, Gross TG
    How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.
    Blood. 2018 May 16. pii: blood-2018-04-844472. doi: 10.1182/blood-2018-04-844472
    PubMed     Text format     Abstract available


  86. CLOT G, Jares P, Gine E, Navarro A, et al
    A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.
    Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136
    PubMed     Text format     Abstract available


  87. MANSON G, Herbaux C, Brice P, Bouabdallah K, et al
    Prolonged remissions after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
    Blood. 2018 May 3. pii: blood-2018-03-841262. doi: 10.1182/blood-2018-03-841262.
    PubMed     Text format    


  88. HU S, Wang Y
    Diffuse large B-cell lymphoma with strong aberrant expression of CD31.
    Blood. 2018;131:2090.
    PubMed     Text format    


  89. HERBAUX C, Merryman R, Devine S, Armand P, et al
    Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
    Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
    PubMed     Text format     Abstract available


  90. CERIANI L, Milan L, Martelli M, Ferreri AJM, et al
    Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
    Blood. 2018 May 2. pii: blood-2018-01-826958. doi: 10.1182/blood-2018-01-826958.
    PubMed     Text format     Abstract available


    April 2018
  91. LACASCE AS, Bociek RG, Sawas A, Caimi P, et al
    Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    Blood. 2018 Apr 27. pii: blood-2017-11-815183. doi: 10.1182/blood-2017-11-815183
    PubMed     Text format     Abstract available


  92. PHILLIPS TJ, Forero-Torres A, Sher T, Diefenbach CS, et al
    Phase 1 study of the PI3Kdelta inhibitor INCB040093 +/- JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
    Blood. 2018 Apr 25. pii: blood-2017-10-812701. doi: 10.1182/blood-2017-10-812701
    PubMed     Text format     Abstract available


  93. HIGUCHI H, Yamakawa N, Imadome KI, Yahata T, et al
    Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma.
    Blood. 2018 Apr 22. pii: blood-2017-07-794529. doi: 10.1182/blood-2017-07-794529
    PubMed     Text format     Abstract available


  94. CHUNG BM, Zieske AW
    Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index.
    Blood. 2018;131:1874.
    PubMed     Text format    


  95. BACHY E, Maurer MJ, Habermann TM, Gelas-Dore B, et al
    A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
    Blood. 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405
    PubMed     Text format     Abstract available


  96. KUPPERS R, Stevenson FK
    Critical influences on the pathogenesis of follicular lymphoma.
    Blood. 2018 Apr 17. pii: blood-2017-11-764365. doi: 10.1182/blood-2017-11-764365
    PubMed     Text format     Abstract available


  97. PASQUALUCCI L, Dalla-Favera R
    Genetics of diffuse large B cell lymphoma.
    Blood. 2018 Apr 17. pii: blood-2017-11-764332. doi: 10.1182/blood-2017-11-764332
    PubMed     Text format     Abstract available


  98. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Text format     Abstract available


  99. JETHWA A, Slabicki M, Hullein J, Jentzsch M, et al
    TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Blood. 2018 Apr 13. pii: blood-2017-09-806679. doi: 10.1182/blood-2017-09-806679
    PubMed     Text format     Abstract available


  100. TIACCI E, Ladewig E, Schiavoni G, Penson A, et al
    Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
    Blood. 2018 Apr 12. pii: blood-2017-11-814913. doi: 10.1182/blood-2017-11-814913
    PubMed     Text format     Abstract available


  101. KUBOTA Y, Kusaba K
    Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system.
    Blood. 2018;131:1765.
    PubMed     Text format    


  102. JIANG X, Zhou D
    ALK(+) small cell variant of anaplastic large cell lymphoma with leukemic presentation.
    Blood. 2018;131:1764.
    PubMed     Text format    


  103. WHITESIDE TL
    Lymphoma exosomes reprogram the bone marrow.
    Blood. 2018;131:1635-1636.
    PubMed     Text format    


  104. STELLING A, Hashwah H, Bertram K, Manz MG, et al
    The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.
    Blood. 2018 Apr 3. pii: blood-2017-10-810630. doi: 10.1182/blood-2017-10-810630.
    PubMed     Text format     Abstract available


    March 2018
  105. YAMAGUCHI M, Suzuki R, Oguchi M
    Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Blood. 2018 Mar 30. pii: blood-2017-12-791418. doi: 10.1182/blood-2017-12-791418
    PubMed     Text format     Abstract available


  106. BATTISTELLO E, Katanayeva N, Dheilly E, Tavernari D, et al
    Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
    Blood. 2018 Mar 22. pii: blood-2017-10-809210. doi: 10.1182/blood-2017-10-809210
    PubMed     Text format     Abstract available


  107. COTTEREAU AS, Versari A, Luminari S, Dupuis J, et al
    Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
    Blood. 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
    PubMed     Text format     Abstract available


  108. WANG HY, Jaffe ES
    An anaplastic T-cell lymphoma mimicking classical Hodgkin lymphoma.
    Blood. 2018;131:1262.
    PubMed     Text format    


  109. BRICE P
    Refractory Hodgkin lymphoma: time for targeted therapies?
    Blood. 2018;131:1156-1157.
    PubMed     Text format    


  110. REN W, Ye X, Su H, Li W, et al
    Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.
    Blood. 2018 Mar 15. pii: blood-2017-11-817601. doi: 10.1182/blood-2017-11-817601
    PubMed     Text format     Abstract available


  111. SMITH M, Zakrzewski J, James S, Sadelain M, et al
    Posttransplant chimeric antigen receptor therapy.
    Blood. 2018;131:1045-1052.
    PubMed     Text format     Abstract available


  112. ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
    ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Blood. 2018;131:1094-1105.
    PubMed     Text format     Abstract available


  113. SCHRADER AMR, Jansen PM, Willemze R, Vermeer MH, et al
    High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
    Blood. 2018 Mar 7. pii: blood-2017-12-822817. doi: 10.1182/blood-2017-12-822817.
    PubMed     Text format    


  114. MOTTOK A, Steidl C
    Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.
    Blood. 2018 Mar 2. pii: blood-2017-09-772632. doi: 10.1182/blood-2017-09-772632.
    PubMed     Text format     Abstract available


  115. BROCKELMANN PJ, Sasse S, Engert A
    Early-stage classical Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-10-772665. doi: 10.1182/blood-2017-10-772665.
    PubMed     Text format     Abstract available


  116. LIM SH, Johnson PWM
    Optimizing therapy in advanced stage Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-09-772640. doi: 10.1182/blood-2017-09-772640.
    PubMed     Text format     Abstract available


  117. SEHN LH
    Introduction to a review series on Hodgkin Lymphoma: Change is here.
    Blood. 2018 Mar 2. pii: blood-2018-02-824045. doi: 10.1182/blood-2018-02-824045.
    PubMed     Text format    


  118. MEHTA-SHAH N, Bartlett NL
    Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
    Blood. 2018 Mar 2. pii: blood-2017-09-772681. doi: 10.1182/blood-2017-09-772681.
    PubMed     Text format     Abstract available


  119. SHAH GL, Moskowitz CH
    Transplant strategies in relapsed/refractory Hodgkin lymphoma.
    Blood. 2018 Mar 2. pii: blood-2017-09-772673. doi: 10.1182/blood-2017-09-772673.
    PubMed     Text format     Abstract available



  120. Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017;130(20):2180-2185.
    Blood. 2018;131:1037.
    PubMed     Text format    


    February 2018
  121. SCOTT DW, King RL, Staiger AM, Ben-Neriah S, et al
    High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
    Blood. 2018 Feb 23. pii: blood-2017-12-820605. doi: 10.1182/blood-2017-12-820605
    PubMed     Text format     Abstract available


  122. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.
    PubMed     Text format    


  123. BRAUE JA, Daniels AB, Zwerner JP, Kim SJ, et al
    Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4(+) to CD8<sup/>.
    Blood. 2018;131:932-935.
    PubMed     Text format    


  124. VIGANO E, Gunawardana J, Mottok A, Van Tol T, et al
    Somatic IL4R Mutations in Primary Mediastinal Large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.
    Blood. 2018 Feb 21. pii: blood-2017-09-808907. doi: 10.1182/blood-2017-09-808907
    PubMed     Text format     Abstract available


  125. VARI F, Arpon D, Keane C, Hertzberg MS, et al
    Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
    Blood. 2018 Feb 15. pii: blood-2017-07-796342. doi: 10.1182/blood-2017-07-796342
    PubMed     Text format     Abstract available


  126. SPINA V, Bruscaggin A, Cuccaro A, Martini M, et al
    Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma.
    Blood. 2018 Feb 15. pii: blood-2017-11-812073. doi: 10.1182/blood-2017-11-812073
    PubMed     Text format     Abstract available


  127. ZHAO X, Tao J
    BRD4: epigenetic origin and target of CTCL.
    Blood. 2018;131:712-713.
    PubMed     Text format    


  128. WASIK MA
    Distinct miRNA profile in prognosis of early CTCL.
    Blood. 2018;131:711.
    PubMed     Text format    


  129. LINDAHL LM, Besenbacher S, Rittig AH, Celis P, et al
    Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study.
    Blood. 2018;131:759-770.
    PubMed     Text format     Abstract available


  130. GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
    CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
    Blood. 2018;131:611-620.
    PubMed     Text format     Abstract available



  131. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
    Blood. 2018;131:587-588.
    PubMed     Text format    


  132. COTTEREAU AS, Versari A, Loft A, Casasnovas O, et al
    Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial.
    Blood. 2018 Feb 1. pii: blood-2017-07-795476. doi: 10.1182/blood-2017-07-795476.
    PubMed     Text format     Abstract available


  133. JIANG W, Zhou X, Li Z, Liu K, et al
    Prolyl 4-Hydroxylase 2 Promotes B-cell Lymphoma Progression via Hydroxylation of Carabin.
    Blood. 2018 Feb 1. pii: blood-2017-07-794875. doi: 10.1182/blood-2017-07-794875.
    PubMed     Text format     Abstract available


    January 2018
  134. VOSE JM
    Peripheral T-cell lymphoma: novel backbone.
    Blood. 2018;131:375-376.
    PubMed     Text format    


  135. ZIJLSTRA JM, Boellaard R
    Baseline PET as prognostic marker for Hodgkin?
    Blood. 2018;131:3-4.
    PubMed     Text format    


  136. XU-MONETTE ZY, Zhou J, Young KH
    PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Blood. 2018;131:68-83.
    PubMed     Text format     Abstract available


  137. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Text format     Abstract available


    December 2017
  138. BATTISTELLA M, Leboeuf C, Ram-Wolff C, Hurabielle C, et al
    KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Blood. 2017;130:2900-2902.
    PubMed     Text format    


  139. FRIEDBERG JW, Forero-Torres A, Bordoni RE, Cline VJM, et al
    Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL.
    Blood. 2017;130:2829-2837.
    PubMed     Text format     Abstract available


  140. ZINZANI PL
    ALCL: is it now a curable disease?
    Blood. 2017;130:2691-2692.
    PubMed     Text format    


  141. HORWITZ SM, Koch R, Porcu P, Oki Y, et al
    Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.
    Blood. 2017 Dec 12. pii: blood-2017-08-802470. doi: 10.1182/blood-2017-08-802470
    PubMed     Text format     Abstract available


  142. HERRERA AF, Moskowitz AJ, Bartlett NL, Vose JM, et al
    Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
    Blood. 2017 Dec 11. pii: blood-2017-10-811224. doi: 10.1182/blood-2017-10-811224
    PubMed     Text format     Abstract available


    November 2017
  143. STEIDL C
    The ecosystem of classical Hodgkin lymphoma.
    Blood. 2017;130:2360-2361.
    PubMed     Text format    


  144. KOHNKEN R, Wen J, Mundy-Bosse B, McConnell K, et al
    Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Blood. 2017 Nov 27. pii: blood-2017-09-805663. doi: 10.1182/blood-2017-09-805663
    PubMed     Text format     Abstract available


  145. LIU WR, Shipp MA
    Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Blood. 2017;130:2265-2270.
    PubMed     Text format     Abstract available


  146. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.
    PubMed     Text format    


  147. GREEN MR
    Chromatin modifying gene mutations in follicular lymphoma.
    Blood. 2017 Nov 20. pii: blood-2017-08-737361. doi: 10.1182/blood-2017-08-737361
    PubMed     Text format     Abstract available



  148. Diffuse large B-cell lymphoma in the elderly.
    Blood. 2017;130:2235.
    PubMed     Text format    


  149. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  150. GALLAMINI A
    Relapsed/refractory HL: FDG-PET is the trump card.
    Blood. 2017;130:2154-2155.
    PubMed     Text format    


  151. AMENGUAL JE, Lichtenstein R, Lue J, Sawas A, et al
    A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Blood. 2017 Nov 15. pii: blood-2017-09-806737. doi: 10.1182/blood-2017-09-806737
    PubMed     Text format     Abstract available


  152. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  153. MOTTOK A, Jurinovic V, Farinha P, Rosenwald A, et al
    FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens.
    Blood. 2017 Nov 9. pii: blood-2017-08-799080. doi: 10.1182/blood-2017-08-799080.
    PubMed     Text format     Abstract available


  154. RYAN MC, Palanca-Wessels MC, Schimpf B, Gordon KA, et al
    Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
    Blood. 2017;130:2018-2026.
    PubMed     Text format     Abstract available


    October 2017
  155. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  156. FISH K, Sora RP, Schaller SJ, Longnecker R, et al
    EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Blood. 2017 Oct 26. pii: blood-2017-07-796821. doi: 10.1182/blood-2017-07-796821
    PubMed     Text format     Abstract available


  157. BARTLETT NL, Costello BA, LaPlant BR, Ansell SM, et al
    Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial.
    Blood. 2017 Oct 26. pii: blood-2017-09-804641. doi: 10.1182/blood-2017-09-804641
    PubMed     Text format     Abstract available


  158. LAMY T, Damaj G, Soubeyran P, Gyan E, et al
    R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL).
    Blood. 2017 Oct 23. pii: blood-2017-07-793984. doi: 10.1182/blood-2017-07-793984
    PubMed     Text format     Abstract available



  159. Genomic analysis of adult Burkitt lymphoma.
    Blood. 2017;130:1871.
    PubMed     Text format    


  160. PILERI SA
    Understanding lymphoma molecular complexity.
    Blood. 2017;130:1780-1781.
    PubMed     Text format    


  161. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  162. AKHTARI M, Milgrom SA, Pinnix CC, Reddy JP, et al
    Re-classifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
    Blood. 2017 Oct 16. pii: blood-2017-04-773838. doi: 10.1182/blood-2017-04-773838
    PubMed     Text format     Abstract available


  163. BALAKRISHNA JP, Jaffe ES
    Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma.
    Blood. 2017;130:1683.
    PubMed     Text format    


  164. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  165. PRO B, Advani R, Brice P, Bartlett NL, et al
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
    Blood. 2017 Oct 3. pii: blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049.
    PubMed     Text format     Abstract available


  166. CYRENNE BM, Lewis J, Weed J, Carlson K, et al
    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood. 2017 Oct 2. pii: blood-2017-06-792150. doi: 10.1182/blood-2017-06-792150.
    PubMed     Text format     Abstract available


    September 2017

  167. MALT lymphoma prognostic index.
    Blood. 2017;130:1486.
    PubMed     Text format    


  168. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  169. PARK J, Yang J, Wenzel AT, Ramachandran A, et al
    Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
    Blood. 2017;130:1430-1440.
    PubMed     Text format     Abstract available


  170. MISHRA A, Porcu P
    Expanding and expounding the genomic map of CTCL.
    Blood. 2017;130:1389-1390.
    PubMed     Text format    


  171. ROELENS M, Delord M, Ram-Wolff C, Marie-Cardine A, et al
    Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity.
    Blood. 2017;130:1468-1471.
    PubMed     Text format    


  172. MALEK A, Bhagat G
    Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression.
    Blood. 2017;130:1388.
    PubMed     Text format    


  173. STEPHENS DM
    Brentuximab: is it time for a new "B" in ABVD?
    Blood. 2017;130:1281-1282.
    PubMed     Text format    


  174. HERTZBERG M
    High-risk DLBCL: interim PET? Not yet.
    Blood. 2017;130:1277-1278.
    PubMed     Text format    


  175. MARTIN P, Ruan J, Leonard JP
    The potential for chemotherapy-free strategies in mantle cell lymphoma.
    Blood. 2017 Sep 12. pii: blood-2017-05-737510. doi: 10.1182/blood-2017-05-737510
    PubMed     Text format     Abstract available


  176. CAREY CD, Gusenleitner D, Lipschitz M, Roemer MGM, et al
    Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Blood. 2017 Sep 11. pii: blood-2017-03-770719. doi: 10.1182/blood-2017-03-770719
    PubMed     Text format     Abstract available


  177. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  178. TESSON B, Huet S, Grange B, Jallades L, et al
    Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes.
    Blood. 2017;130:1267-1269.
    PubMed     Text format    


  179. MOSKOWITZ AJ, Schoder H, Gavane S, Thoren KL, et al
    Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877.
    PubMed     Text format     Abstract available


    August 2017
  180. KHODARAHMI I, Ghesani N
    Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
    Blood. 2017;130:1174.
    PubMed     Text format    


  181. DAVIDS MS
    Targeting BCL-2 in B-cell lymphomas.
    Blood. 2017;130:1081-1088.
    PubMed     Text format     Abstract available


  182. KREMER KN, Dinkel BA, Sterner RM, Osborne DG, et al
    TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.
    Blood. 2017;130:982-994.
    PubMed     Text format     Abstract available


  183. ESKELUND CW, Dahl C, Hansen JW, Westman M, et al
    TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
    Blood. 2017 Aug 17. pii: blood-2017-04-779736. doi: 10.1182/blood-2017-04-779736
    PubMed     Text format     Abstract available


  184. LIN RJ, Behera M, Diefenbach CS, Flowers CR, et al
    The Role of Anthracycline and Comprehensive Geriatric Assessment for Elderly Patients with Diffuse Large B-cell Lymphoma.
    Blood. 2017 Aug 16. pii: blood-2017-05-736975. doi: 10.1182/blood-2017-05-736975
    PubMed     Text format    


  185. BOUSKA A, Bi C, Lone W, Zhang W, et al
    Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
    Blood. 2017 Aug 11. pii: blood-2017-02-767335. doi: 10.1182/blood-2017-02-767335
    PubMed     Text format     Abstract available


  186. SALAR A, Domingo-Domenech E, Panizo C, Nicolas C, et al
    Long-term results of a phase II study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
    Blood. 2017 Aug 11. pii: blood-2017-07-795302. doi: 10.1182/blood-2017-07-795302
    PubMed     Text format    


  187. OKONKWO L, Jaffe ES
    Intravascular large cell lymphoma of NK/T-cell type, EBV positive.
    Blood. 2017;130:837.
    PubMed     Text format    


  188. NAM AS, Tam W
    An intrasinusoidal extracavitary variant of primary effusion lymphoma.
    Blood. 2017;130:836.
    PubMed     Text format    


  189. WEIGERT O, Weinstock DM
    The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
    Blood. 2017 Aug 7. pii: blood-2017-07-737353. doi: 10.1182/blood-2017-07-737353.
    PubMed     Text format     Abstract available


  190. CRUMP M, Neelapu SS, Farooq U, Van Den Neste E, et al
    Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
    Blood. 2017 Aug 3. pii: blood-2017-03-769620. doi: 10.1182/blood-2017-03-769620.
    PubMed     Text format     Abstract available


  191. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  192. TSUYAMA N, Sakata S, Baba S, Mishima Y, et al
    BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
    Blood. 2017;130:489-500.
    PubMed     Text format     Abstract available


  193. DOMINGUEZ-SOLA D
    SOX11 holds mantle cell lymphoma's key to home.
    Blood. 2017;130:389-391.
    PubMed     Text format    


  194. EICHENAUER DA, Engert A
    R-CHOP in NLPHL: who should receive it?
    Blood. 2017;130:387-388.
    PubMed     Text format    


  195. COURTOIS L, Sujobert P
    Morphologic features of mu-heavy-chain disease.
    Blood. 2017;130:558.
    PubMed     Text format    


  196. CONNORS JM, Ansell SM, Fanale M, Park SI, et al
    Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma.
    Blood. 2017 Jul 21. pii: blood-2017-05-784678. doi: 10.1182/blood-2017-05-784678
    PubMed     Text format    



  197. Predicting transformation of follicular lymphoma.
    Blood. 2017;130:383.
    PubMed     Text format    


  198. GONG S, Hijiya N
    Classical Hodgkin lymphoma and Castleman disease: a rare morphologic combination.
    Blood. 2017;130:381.
    PubMed     Text format    


  199. FEHNIGER TA
    CD70 turns on NK cells to attack lymphoma.
    Blood. 2017;130:238-239.
    PubMed     Text format    


  200. CABANILLAS F, Rivera N
    Check this checkpoint inhibitor in lymphoma.
    Blood. 2017;130:234-235.
    PubMed     Text format    


  201. ERDMANN T, Klener P, Lynch JT, Grau M, et al
    Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Blood. 2017;130:310-322.
    PubMed     Text format     Abstract available


  202. THIEBLEMONT C, Cascione L, Conconi A, Kiesewetter B, et al
    A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial.
    Blood. 2017 Jul 18. pii: blood-2017-03-771915. doi: 10.1182/blood-2017-03-771915
    PubMed     Text format     Abstract available


  203. WOODS DM, Woan KV, Cheng F, Sodre AL, et al
    T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.
    Blood. 2017;130:146-155.
    PubMed     Text format     Abstract available


  204. CASASNOVAS RO, Ysebaert L, Thieblemont C, Bachy E, et al
    A FDG-PET driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase II study.
    Blood. 2017 Jul 12. pii: blood-2017-02-766691. doi: 10.1182/blood-2017-02-766691
    PubMed     Text format     Abstract available


  205. SZYDLOWSKI M, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Derezinska E, et al
    Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Blood. 2017 Jul 11. pii: blood-2017-01-760702. doi: 10.1182/blood-2017-01-760702
    PubMed     Text format     Abstract available


    June 2017
  206. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    


  207. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  208. HAVRANEK O, Xu J, Kohrer S, Wang Z, et al
    Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-10-747303. doi: 10.1182/blood-2016-10-747303
    PubMed     Text format     Abstract available


  209. CHIN CK, Cheah CY
    How I treat patients with aggressive lymphoma at high risk of CNS relapse.
    Blood. 2017 Jun 13. pii: blood-2017-03-737460. doi: 10.1182/blood-2017-03-737460
    PubMed     Text format     Abstract available


  210. FRIEDBERG JW
    How I treat "Double Hit" lymphoma.
    Blood. 2017 Jun 9. pii: blood-2017-04-737320. doi: 10.1182/blood-2017-04-737320.
    PubMed     Text format     Abstract available


  211. CHRISTIAN B
    Checkpoint inhibition in CNS lymphoma.
    Blood. 2017;129:3045-3046.
    PubMed     Text format    


  212. ZHANG H, Chen Z, Miranda RN, Medeiros LJ, et al
    Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
    Blood. 2017 Jun 7. pii: blood-2017-02-767293. doi: 10.1182/blood-2017-02-767293.
    PubMed     Text format     Abstract available


    May 2017
  213. GILL K
    CD5-negative mantle cell lymphoma of the breast.
    Blood. 2017;129:2950.
    PubMed     Text format    


  214. SCHMIDT J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, et al
    Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.
    Blood. 2017 May 22. pii: blood-2017-03-776278. doi: 10.1182/blood-2017-03-776278
    PubMed     Text format     Abstract available


  215. BALSAS P, Palomero J, Eguileor A, Rodriguez ML, et al
    SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
    Blood. 2017 May 22. pii: blood-2017-04-776740. doi: 10.1182/blood-2017-04-776740
    PubMed     Text format     Abstract available


  216. FANALE MA, Cheah CY, Rich A, Medeiros LJ, et al
    Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Blood. 2017 May 18. pii: blood-2017-02-766121. doi: 10.1182/blood-2017-02-766121
    PubMed     Text format     Abstract available


  217. PEDERSEN MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, et al
    DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.
    Blood. 2017 May 18. pii: blood-2016-12-755496. doi: 10.1182/blood-2016-12-755496
    PubMed     Text format    


  218. GAY C, Delarue R, Milpied N, Oberic L, et al
    Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.
    Blood. 2017;129:2811-2813.
    PubMed     Text format    


  219. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  220. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  221. TOUT M, Casasnovas O, Meignan M, Lamy T, et al
    Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
    Blood. 2017;129:2616-2623.
    PubMed     Text format     Abstract available


  222. ZINZANI PL, Ribrag V, Moskowitz CH, Michot JM, et al
    Safety & tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
    Blood. 2017 May 10. pii: blood-2016-12-758383. doi: 10.1182/blood-2016-12-758383
    PubMed     Text format     Abstract available


  223. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  224. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  225. HAVERKOS BM, Abbott D, Hamadani M, Armand P, et al
    PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346.
    PubMed     Text format     Abstract available


  226. KURUVILLA J, Savona M, Baz R, Mau-Sorensen M, et al
    Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma.
    Blood. 2017 May 3. pii: blood-2016-11-750174. doi: 10.1182/blood-2016-11-750174.
    PubMed     Text format     Abstract available


    April 2017
  227. JACCARD A, Hermine O
    A major turning point in NK/T-cell lymphoma?
    Blood. 2017;129:2342-2343.
    PubMed     Text format    


  228. BUJISIC B, De Gassart A, Tallant R, Demaria O, et al
    Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Blood. 2017;129:2420-2428.
    PubMed     Text format     Abstract available


  229. CHIECCHIO L, Cullis JO
    De novo Richter transformation.
    Blood. 2017;129:2455.
    PubMed     Text format    



  230. Risk of heart failure following Hodgkin lymphoma.
    Blood. 2017;129:2334.
    PubMed     Text format    


  231. BHATT S, Parvin S, Zhang Y, Cho HM, et al
    Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Blood. 2017;129:2246-2256.
    PubMed     Text format     Abstract available


  232. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  233. LE GOUILL S, Casasnovas RO
    Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?
    Blood. 2017 Apr 17. pii: blood-2016-05-672196. doi: 10.1182/blood-2016-05-672196
    PubMed     Text format     Abstract available


  234. KRIDEL R, Sehn LH, Gascoyne RD
    Can histologic transformation of follicular lymphoma be predicted and prevented?
    Blood. 2017 Apr 13. pii: blood-2017-03-691345. doi: 10.1182/blood-2017-03-691345
    PubMed     Text format     Abstract available


  235. MILLER HK, Santo L, Camargo MC, Winkler CA, et al
    Coxiella burnetii antibody seropositivity is not a risk factor for AIDS-related non-Hodgkin lymphoma.
    Blood. 2017 Apr 10. pii: blood-2016-12-756569. doi: 10.1182/blood-2016-12-756569
    PubMed     Text format    


  236. KAKKASSERY V, Schroers R, Coupland SE, Wunderlich MI, et al
    Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma.
    Blood. 2017 Apr 7. pii: blood-2017-01-765180. doi: 10.1182/blood-2017-01-765180.
    PubMed     Text format    


    March 2017
  237. KAWASAKI K, Karube K
    Peripheral T-cell lymphoma with EBV-infected "anaplastic" B-cell proliferation confined to sinuses.
    Blood. 2017;129:1885.
    PubMed     Text format    


  238. ALINARI L
    Toward autophagy-targeted therapy in lymphoma.
    Blood. 2017;129:1740-1742.
    PubMed     Text format    


  239. NAYAK L, Iwamoto FM, LaCasce A, Mukundan S, et al
    PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Blood. 2017 Mar 29. pii: blood-2017-01-764209. doi: 10.1182/blood-2017-01-764209
    PubMed     Text format     Abstract available


  240. ENNISHI D, Mottok A, Ben-Neriah S, Shulha HP, et al
    Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact.
    Blood. 2017 Mar 28. pii: blood-2016-11-747022. doi: 10.1182/blood-2016-11-747022
    PubMed     Text format     Abstract available


  241. GOPAL AK, Kahl BS, Flowers CR, Martin P, et al
    Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Blood. 2017 Mar 21. pii: blood-2016-12-757740. doi: 10.1182/blood-2016-12-757740
    PubMed     Text format    


  242. JAHN L, Hombrink P, Hagedoorn RS, Kester MG, et al
    TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
    Blood. 2017;129:1284-1295.
    PubMed     Text format     Abstract available


  243. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    


    February 2017
  244. CHONG EA, Melenhorst JJ, Lacey SF, Ambrose DE, et al
    PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
    Blood. 2017;129:1039-1041.
    PubMed     Text format    


  245. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


    January 2017
  246. ABRAMSON JS
    Recurrent mutations and targeted therapy in FL.
    Blood. 2017;129:402-403.
    PubMed     Text format    


  247. SESQUES P, Johnson NA
    Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Blood. 2017;129:280-288.
    PubMed     Text format     Abstract available


  248. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  249. YAHALOM J
    Curative radiation for orbital MZL: how much?
    Blood. 2017;129:270-271.
    PubMed     Text format    


  250. KUO SH, Chen LT, Lin CW, Yeh KH, et al
    Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.
    Blood. 2017;129:188-198.
    PubMed     Text format     Abstract available


  251. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.
    PubMed     Text format    


  252. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.
    PubMed     Text format    


  253. STEIDL C
    Exposing Hodgkin-Reed-Sternberg cells.
    Blood. 2017;129:6-7.
    PubMed     Text format    


    December 2016
  254. HUANG Q
    A striking bone marrow dyserythropoietic change but no anemia.
    Blood. 2016;128:3177.
    PubMed     Text format    


  255. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Text format     Abstract available


    November 2016
  256. VILLA D
    Novel antivirals for HCV-associated lymphomas.
    Blood. 2016;128:2482-2483.
    PubMed     Text format    


    September 2016
  257. ARCAINI L, Besson C, Frigeni M, Fontaine H, et al
    Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Blood. 2016 Sep 7. pii: blood-2016-05-714667.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: